Eisai partners with PharmStandard to localise production in Russia

6 April 2016 (Last Updated April 6th, 2016 18:30)

Eisai has collaborated with Russian pharmaceutical company PharmStandard to localise production of its products in the country.

Eisai

Eisai has collaborated with Russian pharmaceutical company PharmStandard to localise production of its products in the country.

As per the agreed terms, Eisai will produce its oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as epilepsy therapy, Fycompa (perampanel) at PharmStandard's facilities.

PharmStandard will complete important stages in the manufacturing process of both eribulin and lenvatinib in its facilities in Ufa, while for perampanel these will be performed in its facility in Kursk.

Eisai Russia general manager Olga Konopleva said: "This is an important step forward for the establishment of Eisai in Russia.

"Through this arrangement with PharmStandard, we can ensure that Russian patients will have access to our innovative drugs, eribulin, lenvatinib and perampanel.

"Our presence in Russia continues to grow and we are pleased to partner with this leading company to increase our value to patients and their families."

Eribulin was registered in Russia in July 2012, and was made available for patients with locally advanced or metastatic breast cancer who have progressed after at least one course of chemotherapy for advanced disease from September 2013.

"Our presence in Russia continues to grow and we are pleased to partner with this leading company to increase our value to patients and their families."

Lenvatinib was registered in Russia in December 2015 and will be accessible for treatment of radioactive iodine refractory differentiated thyroid cancer from June this year.

Perampanel was registered in August 2013 in Russia as adjunctive treatment for patients with partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

Additionally, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recently issued a positive opinion on Eisai's anticancer agent Halaven (eribulin mesylate).

Halaven is indicated for treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.


Image: Eisai head office in Tokyo, Japan. Photo: courtesy of KW.